Occam Places Craig Thompson as CEO at Cerevance
Cerevance, a private, clinical-stage drug discovery and development company focused on central nervous system diseases, has brought on Craig Thompson as Chief Executive Officer. Craig brings over 25 years of commercial and marketing leadership experience in the biotech and pharmaceutical industries to the company.
Craig recently served as President and CEO at Neurana Pharmaceuticals, a private company focused on the treatment of neuromuscular conditions. Prior to Neurana, he served as President and CEO of Anthera Pharmaceuticals, and before that, as Chief Operating Officer of Tetraphase Pharmaceuticals, where he oversaw the development and implementation of the marketing, access, reimbursement and sales strategy, as well as business development and commercial manufacturing. Prior to Tetraphase, he was Chief Commercial Officer for Trius Therapeutics, which was acquired by Cubist Pharmaceuticals for more than $700 million. Earlier in his career, Craig served in various commercial and marketing roles of increasing responsibility at Pfizer and Merck. He holds a Bachelor of Commerce degree from McMaster University and an M.B.A. from the University of Notre Dame.
Occam Global is a biotech executive search, recruiting, and leadership advisory firm with specialties across technological fields, including Biotech, TechBio, AI-ML, Cell/Gene Therapy, Diagnostics/Genomics, Medical Devices, Research Tools, Digital Health, Alternative Energy, AgTech, EdTech, Robotics as well as adjacencies within Venture Capital and Private Equity. Occam helps build biotech executive leadership teams that meet the demands of the rapidly developing, competitive, and challenging industries it serves. Occam Global recruits leading C-Suite executives and board members for the most exciting and innovative clients across the world with a specific focus on the UK, Continental Europe, the US, and Asia.